Henan Lingrui Pharmaceutical News

Ling Rui Pharmaceutical (600285): Outstanding performance in the first half of the year, and continued to highlight core competitiveness

Aug 13 00:00

Ling Rui Pharmaceutical (600285): Increased dividend rate, performance exceeded expectations

May 1 00:00

Open Source Securities released a research report on April 26 stating that it gave Ling Rui Pharmaceutical (600285.SH) a purchase rating. The main reasons for the rating include: 1) impressive revenue growth rate for patch, tablet and capsule products, an

Zhitong FinanceApr 26 22:44

Lingrui Pharmaceutical (600285) Company Brief Evaluation Report: The steady growth performance of core products is basically in line with expectations

Oct 31, 2023 00:00

In-depth research on Ling Rui Pharmaceutical (600285): Product Upgrade+Price Increase Cycle Ling Rui Leaps to a New Level

東方財富證券Jun 10, 2022 06:56

Lingrui Pharmaceutical (600285) In-depth Report: Market Share Increase+Price Increase, Two-wheel Drive, Traditional Chinese Medicine Paste, Leading Company Steady Forward

國海證券May 7, 2022 00:00

Lingrui Pharmaceutical (600285): Brands and Channels Drive Company Profit Acceleration

東方財富證券Apr 28, 2022 07:17

Lingrui Pharmaceutical (600285) brief Review report: the performance is in line with the expected patch leader is expected to continue to grow steadily

首創證券Apr 28, 2022 00:00

Lingrui Pharmaceutical (600285) in-depth report: marketing Reform and Terminal Price increase help the Company usher in the second growth Curve

開源證券Dec 10, 2021 00:00

Dynamic comment of Lingrui Pharmaceutical (600285) Company: the performance is in line with expectations and is optimistic about the steady growth for the whole year.

長城證券Sep 1, 2021 00:00

Lingrui Pharmaceutical (600285): Xingshiyuan proprietary Chinese medicine plaster leader

開源證券Jul 30, 2021 00:00

Dynamic comment of Lingrui Pharmaceutical (600285) Co., Ltd.: Q3 performance accelerated growth and continuous optimization of product structure

長城證券Oct 29, 2020 00:00

Dynamic Review of Lingrui Pharmaceutical (600285) Co., Ltd.: low valuation and high quality target to see the company's growth engine from three angles

長城證券Sep 20, 2020 00:00

Lingrui Pharmaceutical (600285) in-depth report: broad product space and low valuation advantage

長城證券Sep 9, 2020 00:00

羚锐制药(600285)：业绩稳健 挖潜骨科

華泰證券Apr 29, 2020 00:00

羚锐制药(600285)：贴膏剂领军企业 战略打造骨科消费龙头

西南證券Nov 24, 2019 00:00

羚锐制药(600285)：Q3稳健增长 骨科+运动医学同步拓展

西南證券Oct 31, 2019 00:00

羚锐制药(600285)：业绩季度改善明显 创新营销驱动增长

國聯證券Oct 30, 2019 00:00

羚锐制药(600285)：主力贴膏品种稳健增长 持续深化营销改革

國聯證券Aug 22, 2019 00:00

羚锐制药(600285)年报点评：期待营销新平台整合放量

華泰證券Apr 29, 2019 00:00